|
Mechanismprotein C stimulants |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date25 Jan 2008 |
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects with Sepsis and Disseminated Intravascular Coagulation
A Randomized, Double-Blind, Placebo-Controlled, Phase-2B Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects With Sepsis and Disseminated Intravascular Coagulation
The purpose of this study is to see if ART-123 (recombinant human soluble thrombomodulin) decreases the number of people who die as a result of Disseminated Intravascular Coagulation (DIC) complication of sepsis.
100 Clinical Results associated with Artisan Pharma, Inc.
0 Patents (Medical) associated with Artisan Pharma, Inc.
100 Deals associated with Artisan Pharma, Inc.
100 Translational Medicine associated with Artisan Pharma, Inc.